## 7 Results
### OT Study Analysis  
For OT, there were just 7 studies for analysis. Study types were described as case reports (n = 1) and case series (n = 6). All these studies were published from 2006 to 2014 (Table 11). A total of 231 patients were reported, 124 female (53.67%) and 74 male (32.03%), with 14.28% of patients (n = 33) of unreported gender. Patients were treated using different OT protocols. The pooled mean of age of these patients was 60.7 years. The most common indications for antiresorptive treatment was multiple myeloma (35.93%), breast cancer (27.70%), prostate cancer (6.49%), lung cancer (6.49), renal cancer (3.46%), uterine cancer (0.43%), non-Hodgkin lymphoma (0.43%) and osteoporosis with lymphoma and thyroid cancer (4.76%). In a significant number of patients (14.28%), the drug therapy indication was not reported (Tables 12 and 13). The most common site for MRONJ was the mandible (43.72%), followed by the maxilla (22.94%). In 8.65% of cases, MRONJ was reported in both, and the site was not reported in 24.67% of cases (Table 12). The drug most commonly responsible for MRONJ was Zoledronate (14.71%). However, only 37 patients out of 231 had details of the specific MRONJ-associated drug reported (16.01%). OT was most commonly used as a neoadjuvant and/or adjuvant therapy, followed by surgery, in 6 studies out of 7 (Table 14). The patients were followed for a period of time ranging from 7 to 36 months. At the end of the follow up, MRONJ was completely resolved in 44.58% of patients (n = 103), whilst 22.94% showed some improvement or remission of the disease (n = 53). No progression of the disease has been reported in any studies (Table 15); however, for 30 patients (12.98%), this data was not available. \begin{table}
\begin{tabular}{c c c c} \hline
**Author(s)** & **Type of Study** & **Total Number of Patients** & **Level of Evidence** \\ \hline \hline \(\;\)[PERSON] et al. 2006 [47] & CS & 30 & Level 4 \\ \(\;\)[PERSON] et al. 2007 [48] & CS & 33 & Level 4 \\ \(\;\)[PERSON] et al. 2011 [49] & CS & 10 & Level 4 \\ \(\;\)[PERSON] et al. 2012 [50] & CS & 131 & Level 4 \\ \(\;\)[PERSON] et al. 2012 [51] & CS & 24 & Level 4 \\ \(\;\)[PERSON] et al. 2013 [52] & CR & 1 & Level 5 \\ \(\;\)[PERSON] et al. 2014 [53] & CS & 2 & Level 4 \\ \hline \hline \end{tabular}
\end{table} 
Table 11: Studies included in the OT analysis, including number of patients treated and evidence level. Case series (CS); Case report (CR); Levels of Evidence for Prognostic Studies Adapted from the American Society of Plastic Surgeons ([[https://www.plasticsurgery.org/Documents/medical-professionals/health-policy/evidence-practice/ASPS-Rating-Scale-March-2011.pdf](https://www.plasticsurgery.org/Documents/medical-professionals/health-policy/evidence-practice/ASPS-Rating-Scale-March-2011.pdf)]([https://www.plasticsurgery.org/Documents/medical-professionals/health-policy/evidence-practice/ASPS-Rating-Scale-March-2011.pdf](https://www.plasticsurgery.org/Documents/medical-professionals/health-policy/evidence-practice/ASPS-Rating-Scale-March-2011.pdf))). \begin{table}
\begin{tabular}{c c c c} \hline \hline
**Study** & **Age/Sex** & **MRONJ Aeliology** & **Site of Necrosis** \\ \hline \multirow{5}{*}{[PERSON] et al. 2006 [47]} & 10 M and 20 E, age ranging from 46 to 79 years old (mean age was 63 years) & & 7 patients (23,3%) in the maxilla; \\  & & & 18 patients (60%) in the mandible; \\  & 79 years old (mean age was 63 years) & & 5 patients presented with exposed \\  & & & \\ \hline \multirow{5}{*}{[PERSON] et al. 2007 [148]} & 12 M and 12 F, & & \\  & age ranging (41-80 years old) & & NR & NR \\  & 62.5 years old) & & NR & NR \\ \hline \multirow{5}{*}{[PERSON] et al. 2013 [52]} & 1 E, 68-year-old & & \\  & & & \\ \cline{1-1}  & & & \\ \cline{1-1}  & & & \\ \cline{1-1}  & & & \\ \cline{1-1}  & & & \\ \cline{1-1}  & & & \\ \cline{1-1}  & & & \\ \hline \hline \end{tabular}
\end{table} 
Table 12: OT Preoperative epidemiologic analysis (age, sex, predisposing factors, and site of the necrosis involved). Male (M); female (F); not reported (NR).